Vojtech Kulvait

Vojtech Kulvait

Auto-generated profile, based on publicly available information

Vojtech Kulvait

BIOCEV, 1st Medical Faculty, Charles University, Vestec, Czech Republic

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 April 2011 in Blood
Verified
Journal Article
Closed access
PDF file
KVKarina Savvulidi Vargova
Karina Savvulidi Vargova
NCNikola Curik
Nikola Curik
PBPavel Burda
Pavel Burda
PBPetra Bašová
Petra Bašová
VKVojtech Kulvait
Vojtech Kulvait
TSTomas Stopka
Tomas Stopka
Elevated levels of microRNA miR-155 represent a candidate pathogenic factor in chronic B-lymphocytic leukemia (B-CLL). In this study, we present evidence that MYB (v-myb myeloblastosis viral oncogene homolog) is overexpressed in a subset of B-CLL patients. MYB physically associates with the promoter of miR-155 host gene (MIR155HG, also known as BIC, B-cell integration cluster) and stimulates its transcription. This coincides with the hypermethylated histone H3K4 residue and spread hyperacetylation of H3K9 at MIR155HG promoter. Our data provide evidence of oncogenic activities of MYB in B-CLL that include its stimulatory role in MIR155HG transcription.

16 October 2012 in International Journal of Fracture
Verified
Journal Article
Closed access
PDF file
VKVojtěch Kulvait
Vojtěch Kulvait
JMJosef Málek
Josef Málek
KRKumbakonam Rajagopal
Kumbakonam Rajagopal

4 November 2014 in Journal of Cancer Research and Clinical Oncology
Verified
Journal Article
Closed access
PDF file
KPKaterina Machova Polakova
Katerina Machova Polakova
VKVojtech Kulvait
Vojtech Kulvait
ABAdela Benesova
Adela Benesova
JLJana Linhartova
Jana Linhartova
HKHana Klamova
Hana Klamova
Simona SoveriniSimona Soverini
Simona Soverini

15 April 2017 in Stem Cells
Verified
Journal Article
Closed access
PDF file
JKJuraj Kokavec
Juraj Kokavec
TZTomas Zikmund
Tomas Zikmund
Filipp Georgijevic SavvulidiFilipp Georgijevic Savvulidi
Filipp Georgijevic Savvulidi
VKVojtech Kulvait
Vojtech Kulvait
WEWinfried Edelmann
Winfried Edelmann
TSTomas Stopka
Tomas Stopka

27 June 2014 in Molecular Cancer
Verified
Journal Article
Open access
PDF file
MKMagdalena Klanova
Magdalena Klanova
LLLucie Lorkova
Lucie Lorkova
OVOndrej Vit
Ondrej Vit
BMBokang Maswabi
Bokang Maswabi
JMJan Molinsky
Jan Molinsky
PKPavel Klener
Pavel Klener
Mantle cell lymphoma (MCL) is an aggressive type of B-cell non-Hodgkin lymphoma associated with poor prognosis. Implementation of high-dose cytarabine (araC) into induction therapy became standard-of-care for all newly diagnosed younger MCL patients. However, many patients relapse even after araC-based regimen. Molecular mechanisms responsible for araC resistance in MCL are unknown and optimal treatment strategy for relapsed/refractory MCL patients remains elusive.

Verified
Journal Article
Open access
PDF file
NDNina Dusílková
Nina Dusílková
PBPetra Bašová
Petra Bašová
JPJindřich Polívka
Jindřich Polívka
OKOndrej Kodet
Ondrej Kodet
VKVojtěch Kulvait
Vojtěch Kulvait
TSTomas Stopka
Tomas Stopka
Primary cutaneous T-cell lymphomas (CTCL) affect the skin and tend to transform and spread. CTCL involves primarily the Mycosis fungoides (MF) and more aggressive Sezary syndrome (SS). Oncogenic microRNAs (miRs) are stable epigenetic inhibitors often deregulated in the tumour and detectable as biomarkers in non-cellular fractions of peripheral blood. The tumour-specific expression of miR-155, miR-203, and miR-205 was shown to correctly diagnose CTCL. We herein asked whether these microRNAs can be used as plasma biomarkers for clinical CTCL monitoring. Patients with CTCL (n = 10) and controls with non-malignant conditions (n = 11) repeatedly donated plasma samples every ca. five months. MicroRNAs were detected in the plasma samples by specifically-primed RT-PCR followed by multivariate analyses of the miR expression dynamics. We herein established the plasma miR-classifier for detecting CTCL based on the miR-155 upregulation and miR-203/miR-205 downregulation with 100% specificity and 94% sensitivity. The 3-miR-score in the consecutive samples coincided with the clinical outcome of MF and SS patients such as the therapy response or changes in the clinical stage or tumor size. Quantitation of the selected microRNAs in plasma is a specific and straightforward approach for evaluating CTCL outcome representing, thus, a valuable tool for CTCL diagnostics and therapy response monitoring.